Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04733495
Other study ID # OSU-19113
Secondary ID NCI-2020-13834
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date April 19, 2021
Est. completion date December 31, 2024

Study information

Verified date May 2024
Source Ohio State University Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial examines a group-mediated cognitive behavioral resistance exercise intervention in head and neck cancer patients who are undergoing chemoradiation treatment. Chemoradiation is the established standard of care for locally advanced head and neck cancer patients. However, many head and neck cancer patients experience clinically meaningful declines in muscle mass, physical function, and quality of life during and following treatment. Resistance exercise has been shown to improve muscle mass, body composition, and physical function when integrated with appropriate standard of care nutritional counseling/supplementation. This trial may help researchers determine the important of integrating exercise interventions with routine cancer care.


Description:

PRIMARY OBJECTIVES: I. To determine the feasibility of implementing a group-mediated cognitive behavioral (GMCB) personalized resistance exercise (RE) intervention in head and neck cancer (HNCa) patients undergoing chemoradiation (CRT). II. To examine the effects of GMCB RE intervention upon functional limitations, body composition, and quality of life (QOL) in HNCa patients undergoing CRT. OUTLINE: Patients undergo personalized resistance exercises over 1 hour daily. Patients receive dietary counseling over 60 minutes at week 1 and then over 15-30 minutes weekly for up to 6 weeks. Patients also receive group-based behavioral counseling twice weekly (BIW) in weeks 1-8, once a week (QW) in weeks 9-12, and then twice a month in weeks 13-24.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date December 31, 2024
Est. primary completion date February 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with locally advanced human papillomavirus (HPV)+ stage III-IV head and neck (HN) squamous cell carcinomas undergoing concurrent chemotherapy and radiation therapy. Patients with prior cancers or post-surgical patients needing adjuvant therapy will not be allowed to participate in this study - Undergoing planned course of standard of care CRT for a total of 33 to 35 RT fractions (six and a half or seven weeks of treatment) - Adults 18 years old (yo) or older who have clearance from their primary care provider (PCP) or medical oncologist to participate in resistance exercises during treatment. These patients will be monitored very closely on a weekly basis during the trial - All participants must be free of severe heart or systemic disease or medical contraindications that would make supervised RE participation unsafe - Receive medical clearance to participate from treating primary care physician or Medical Oncologists - Ability to understand and the willingness to sign a written informed consent - Willing and physically able to participate in RE Exclusion Criteria: - Severe heart or systemic disease or medical contraindications to exercise - Diagnosis of cancer other than HNCa - Musculoskeletal/Neurological disorder inhibiting them from safe exercise - Pregnant or nursing women - Unable to give informed consent

Study Design


Related Conditions & MeSH terms

  • Head and Neck Neoplasms
  • Locally Advanced Head and Neck Squamous Cell Carcinoma
  • Squamous Cell Carcinoma of Head and Neck

Intervention

Other:
Counseling
Receive group-based behavioral counseling
Behavioral:
Dietary Counseling and Surveillance
Receive dietary counseling
Other:
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Resistance Training
Undergo personalized resistance exercises

Locations

Country Name City State
United States Ohio State University Comprehensive Cancer Center Columbus Ohio

Sponsors (1)

Lead Sponsor Collaborator
Ohio State University Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recruitment rates Number of patients agreed to participate by signing the informed consent At baseline
Primary Adherence of Intervention Adherence will be defined via session attendance and compliance with the prescribed sets, repetitions, and loads of the RE prescription as assessed using exercise logs, upon which participants will record all exercise performed at the center or independently.. At 3-month
Primary Adherence of Intervention Adherence will be defined via session attendance and compliance with the prescribed sets, repetitions, and loads of the RE prescription as assessed using exercise logs, upon which participants will record all exercise performed at the center or independently.. At 6-month
Primary Incidence of adverse events Monitored by direct observation and or patient reporting of signs and symptoms using NCI CTCAE version 5 At 3-month
Primary Incidence of adverse events Monitored by direct observation and or patient reporting of signs and symptoms using NCI CTCAE version 5 At 6-month
Primary Retention rates Rates will be calculated prospectively throughout the trial At 3-month
Primary Retention rates Rates will be calculated prospectively throughout the trial At 6-month
Primary Functional Battery Functional Battery Objective Functional Performance will be assessed using 3 valid and reliable timed performance-related mobility tasks: 400-meter walk (the primary outcome), stair-climb, and lift and carry task. Assessments of Mobility-Related Self-Efficacy to complete each functional task will also be completed with the tests. At 3-month
Primary Functional Battery Functional Battery Objective Functional Performance will be assessed using 3 valid and reliable timed performance-related mobility tasks: 400-meter walk (the primary outcome), stair-climb, and lift and carry task. Assessments of Mobility-Related Self-Efficacy to complete each functional task will also be completed with the tests. At 6-month
Primary Patient Reported Outcomes (Quality of Life/Fatigue/Physical Function) QoF will be assessed using both global and disease-specific measures including the satisfaction with life scale, the SF-12, the Functional Assessment of Cancer Therapy - Head and Neck (FACT - HN) and the EORTC Quality of Life scale. Fatigue symptoms will be assessed with the Brief Fatigue Inventory (BFI). At 3-month
Primary Patient Reported Outcomes (Quality of Life/Fatigue/Physical Function) QoF will be assessed using both global and disease-specific measures including the satisfaction with life scale, the SF-12, the Functional Assessment of Cancer Therapy - Head and Neck (FACT - HN) and the EORTC Quality of Life scale. Fatigue symptoms will be assessed with the Brief Fatigue Inventory (BFI). At 6-month
Primary Muscular strength Muscular strength will be assessed using standardized one-repetition maximum testing protocols for the chest press and leg extension exercises. At 3-month
Primary Muscular strength Muscular strength will be assessed using standardized one-repetition maximum testing protocols for the chest press and leg extension exercises. At 6-month
Primary Anthropometric measurements Anthropometric measurements are a series of quantitative measurements of the muscle, bone, and adipose tissue used to assess the composition of the body. The core elements of anthropometry are height, weight, body mass index (BMI), body circumferences (waist, hip, and limbs), and skinfold thickness. Anthropometric measurements will be taken in a consultation room to ensure the privacy of the participant. At 3-month
Primary Anthropometric measurements Anthropometric measurements are a series of quantitative measurements of the muscle, bone, and adipose tissue used to assess the composition of the body. The core elements of anthropometry are height, weight, body mass index (BMI), body circumferences (waist, hip, and limbs), and skinfold thickness. Anthropometric measurements will be taken in a consultation room to ensure the privacy of the participant. At 6-month
Primary Body composition Body composition will be assessed using dual-energy x-ray absorptiometry (DEXA; GE Health Care Lunar, Madison, WI) for all outcome measures. The DEXA scans will be used to determine total body composition including bone-mineral density, as well as, percentage body fat and fat-free mass for all body regions. At 3-month
Primary Body composition Body composition will be assessed using dual-energy x-ray absorptiometry (DEXA; GE Health Care Lunar, Madison, WI) for all outcome measures. The DEXA scans will be used to determine total body composition including bone-mineral density, as well as, percentage body fat and fat-free mass for all body regions. At 6-month
See also
  Status Clinical Trial Phase
Completed NCT03426657 - Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC Phase 2
Recruiting NCT05172245 - Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer Phase 1
Completed NCT04949503 - A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN
Completed NCT04870840 - Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer Phase 1
Completed NCT04541355 - Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin Phase 2
Recruiting NCT03649048 - Low-Dose Weekly vs High-Dose Cisplatin N/A
Recruiting NCT05724602 - Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT05773079 - Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT05861557 - Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Recruiting NCT05527782 - Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Phase 2
Recruiting NCT05269381 - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05376553 - Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Phase 1
Withdrawn NCT03875053 - Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer N/A
Recruiting NCT04892173 - NBTXR3 With or Without Cetuximab in LA-HNSCC Phase 3
Withdrawn NCT05743270 - Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN Phase 2
Recruiting NCT06240689 - A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood Phase 2
Suspended NCT04454489 - Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition Phase 2
Completed NCT01689194 - Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer Phase 2
Recruiting NCT05245682 - Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer Early Phase 1
Recruiting NCT04947241 - Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC Phase 1

External Links